Biological monitoring of cancer chemoprevention.
A major limiting factor in the successful implementation of cancer chemoprevention trials has been the determination of endpoints to measure efficacy and success. The use of the ultimate goal of such trials, namely, cancer incidence, as an endpoint has serious feasibility problems, including the need for large numbers of participants, long follow-up periods, and high costs. The application of biological markers as intermediate endpoints to reveal responses to chemopreventive agents within a short time and to act as surrogates for cancer is an attractive concept worthy of intense investigation. This study reviews some potential biological markers, including genetic, cellular, biochemical, and immunological, as well as their possible application to cancer chemoprevention.
Pillai
R
R
Department of Family and Community Medicine, University of Arizona, Tucson 85724.
Garewal
H S
HS
Wood
S
S
Watson
R R
RR
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis; D005819:Genetic Markers; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000378:metabolism / Q000517:prevention & control*; D009752:Nutritional Status; D011230:Precancerous Conditions
D000970:Antineoplastic Agents; D015415:Biomarkers; D014408:Biomarkers, Tumor; D005819:Genetic Markers